Cargando…
Messenger RNA vaccines against SARS-CoV-2
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF.
Autor principal: | Topol, Eric J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805392/ https://www.ncbi.nlm.nih.gov/pubmed/33740443 http://dx.doi.org/10.1016/j.cell.2020.12.039 |
Ejemplares similares
-
RNA sequencing of the nephron transcriptome: a technical note
por: Lee, Jae Wook
Publicado: (2015) -
Endovascular interventions for central vein stenosis
por: Agarwal, Anil K.
Publicado: (2015) -
Current progress in ABO-incompatible kidney transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2015) -
Organ-on-a-chip and the kidney
por: Kim, Sejoong, et al.
Publicado: (2015) -
Neuro-tracing approach to study kidney innervation: a technical note
por: Lee, Sanghee, et al.
Publicado: (2017)